INHIBITOR OF p38 MAP KINASE

Patent metadata

Field	Value
Publication number	US-2021179584-A1
Application number	US-202017031190-A
Country	US
Kind code	A1
Filing date	Sep 24, 2020
Priority date	Feb 14, 2014
Publication date	Jun 17, 2021
Grant date	—

Abstract

A compound has the following formula:The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

First claim

1 - 19 . (canceled)

20 . A method of treatment of a condition selected from exacerbation of COPD and exacerbation of asthma comprising administering to a subject in need thereof an effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

21 . A method of treatment of exacerbation of inflammatory disease in patients with chronic conditions selected from a group consisting of congestive heart failure, diabetes, cancer, and conditions suffered by immunosuppressed patients comprising administering to a subject in need thereof an effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

22 . The method of claim 20 , wherein the exacerbation of COPD or exacerbation of asthma is a virally induced exacerbation.

23 . The method of claim 20 , wherein the condition is exacerbation of COPD.

24 . The method of claim 20 , wherein the COPD is selected from a group consisting of chronic bronchitis and emphysema.

25 . The method of claim 20 , wherein the asthma is paediatric asthma.

26 . The method of claim 20 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof is administered as a dry-powder formulation for inhalation.

27 . The method of claim 26 , wherein the dry-powder formulation for inhalation comprises lactose.

28 . The method of claim 20 , further comprising administering an antiviral agent.

29 . The method of claim 20 , wherein the compound of formula (I) is in its free base form.

30 . The method of claim 20 , wherein the compound of formula (I) is in anhydrous solid crystalline form.

31 . The method of claim 21 , wherein the exacerbation is a virally induced exacerbation.

32 . The method of claim 21 , wherein the conditions suffered by immunosuppressed patients is post-organ transplant.

33 . The method of claim 21 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof is administered as a dry-powder formulation for inhalation.

34 . The method of claim 33 , wherein the dry-powder formulation for inhalation comprises lactose.

35 . The method of claim 21 , further comprising administering an antiviral agent.

36 . The method of claim 21 , wherein the compound of formula (I) is in its free base form.

37 . The method of claim 21 , wherein the compound of formula (I) is in anhydrous solid crystalline form.

Assignees

• Respivert Ltd

Inventors

• Longshaw Alistair Ian
• Fordyce Euan Alexander Fraser
• Onions Stuart Thomas
• King-Underwood John
• Venable Jennifer

Classifications

• A61P27/14

  Decongestants or antiallergics · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• C07D403/14

  containing three or more hetero rings · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title